JON Wilkin has been named as England Captain for t

first_imgJON Wilkin has been named as England Captain for this Wednesday’s International Origin Game Two.England coach Steve McNamara today confirmed debuts for Warrington Wolves utility back Stefan Ratchford while Danny Brough of Huddersfield Giants and Salford City Reds’ Matty Smith will form a new-look half-back partnership, with Hull KR prop Scott Taylor starting from the bench.Wilkin will captain the team after Jamie Peacock’s retirement last month and will partner Leeds Rhinos second row Carl Ablett with Jamie Jones-Buchanan of Leeds starting at loose forward.“We have a young, hungry side that will take on the Exiles on Wednesday,” said national coach McNamara. “We have made a number of changes from the first game and it is an exciting opportunity to see some real quality young players coming in and staking a claim for a regular place in the side.”McNamara is also looking forward to see how Brough and Smith cut it at this level forming a new half-back combination.“Matty (Smith) and Danny (Brough) really excite me,” added McNamara. “They have been in tremendous form in the Stobart Super League and I know they have the ability to step up and perform at this level. They will complement each other’s skills and can form a devastating partnership.”Tickets for the International Origin Series Game 2 fixture between England and the Exiles at Galpharm Stadium, Huddersfield, on Wednesday July 4 (7.45pm) cost from £21 (£10 concessions) and can be purchased through the RFL Ticket office on 0844 856 1113 or by visiting www.rugbyleaguetickets.co.ukEngland: Stefan Ratchford; Josh Charnley, Leroy Cudjoe, Ryan Atkins, Tom Briscoe; Matty Smith, Danny Brough; Eorl Crabtree, James Roby, Garreth Carvell, Carl Ablett, Jon Wilkin, Jamie Jones-Buchanan.Subs: Rob Burrow, Liam Farrell, Lee Mossop, Scott Taylor.last_img read more

Rice lab synthesizes new cancer fighter

first_imghttp://news.rice.edu/files/2016/06/0620_CANCER-1-WEB-276pv25.jpgA schematic shows the synthesized anti-cancer agent Thailanstatin A. The Rice University lab of synthetic chemist K.C. Nicolaou has synthesized the molecule found in bacteria native to Thailand. (Credit: Nicolaou Group/Rice University) http://news.rice.edu/files/2016/06/0620_CANCER-3-WEB-2gvtqs8.jpgK.C. Nicolaou (Credit: Jeff Fitlow/Rice University)Located on a 300-acre forested campus in Houston, Rice University is consistently ranked among the nation’s top 20 universities by U.S. News & World Report. Rice has highly respected schools of Architecture, Business, Continuing Studies, Engineering, Humanities, Music, Natural Sciences and Social Sciences and is home to the Baker Institute for Public Policy. With 3,910 undergraduates and 2,809 graduate students, Rice’s undergraduate student-to-faculty ratio is 6-to-1. Its residential college system builds close-knit communities and lifelong friendships, just one reason why Rice is ranked No. 1 for best quality of life and for lots of race/class interaction by the Princeton Review. Rice is also rated as a best value among private universities by Kiplinger’s Personal Finance. To read “What they’re saying about Rice,” go to http://tinyurl.com/RiceUniversityoverview. Share4Editor’s note: Links to images for download appear at the end of this release.David Ruth713-348-6327david@rice.eduMike Williams713-348-6728mikewilliams@rice.eduRice lab synthesizes new cancer fighterThailanstatin A disrupts disease by inhibiting DNA-editing machinery HOUSTON – (June 20, 2016) – Rice University scientists have synthesized a novel anti-cancer agent, Thailanstatin A, which was originally isolated from a bacterial species collected in Thailand.Thailanstatin A fights cancer by inhibiting the spliceosome, the machinery in the cell that edits messenger RNA after transcription from DNA but before its translation into proteins.Rice synthetic chemist K.C. Nicolaou and his group reported their success in the Journal of the American Chemical Society.Nicolaou and his colleagues specialize in the synthesis of potential therapeutic agents that are found in nature but in amounts too small for thorough biological evaluation or clinical use. He is best known for the total synthesis of paclitaxel, a drug commonly used to treat a number of cancers.The researchers explained that the spliceosome, a complex of proteins and ribonucleoproteins that regulate DNA splicing, is more active and displays higher mutation rates in cancer cells than in healthy cells, which makes it a valid target for investigation.“This cellular machinery edits mRNA as it emerges from the transcription of DNA through site-specific removal of introns (noncoding regions of DNA) and splicing the remaining exon (coding) sequences prior to translation,” Nicolaou said. “Thailanstatin A interferes with this mechanism.”He said the synthesis of Thailanstatin A, first isolated from burkholderia thailandensis bacteria, opens the way to construct and test variations of the molecule. “These studies will be directed toward optimization of the pharmacological properties of this new natural product as part of a drug discovery and development program targeting new therapies for cancer,” Nicolaou said.The program can take two directions, he said: one directed toward high-potency compounds that could be used as payloads for antibody drug conjugates and the other toward selective agents that can kill cancer cells with minimal damage to healthy cells.The first paradigm is currently a frontier approach for the development of targeted and personalized cancer therapies, while the second represents a more traditional approach that could also lead to powerful anti-cancer drugs, Nicolaou said. “Thailanstatin A exhibits just the right potency to be diverted to either approach through a reiterative molecular design, chemical synthesis and biological evaluation process,” he said.“We’re excited about this new molecule and its analogs because of their unique biological properties and the prospects of working collaboratively with industrial and academic partners to advance them toward the clinic,” Nicolaou said.Co-authors of the paper are graduate student Derek Rhoades and postdoctoral researchers Manjunath Lamani, Manas Pattanayak and Mothish Kumar.The Cancer Prevention and Research Institute of Texas and the Welch Foundation supported the research.-30-Read the abstract at http://pubs.acs.org/doi/abs/10.1021/jacs.6b04781.Follow Rice News and Media Relations via Twitter @RiceUNews.Related materials:K.C. Nicolaou Group: http://nicolaou.rice.eduRice University Department of Chemistry: https://chemistry.rice.edu/Images for download:center_img AddThislast_img read more